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IMPORTANCE To our knowledge, the clinical features of ocular adnexal mantle-cell lymphoma
(OA-MCL) have not previously been evaluated in a large multicenter cohort.
OBJECTIVE To characterize the clinical features of OA-MCL.
DESIGN, SETTING, AND PARTICIPANTS This retrospectivemulticenter study included patient
data collected from January 1, 1980, through December 31, 2015, at 6 eye cancer centers in 4
countries. Medical records of 55 patients with OA-MCLwere reviewed; themedian length of
follow-up was 33months.
MAIN OUTCOMES ANDMEASURES Overall survival, disease-specific survival, and
progression-free survival were the primary end points.
RESULTS Fifty-five patients were included; ocular adnexal MCL was found to bemost
common in older individuals (mean age, 70 years) andmen (n = 42 of 55; 76%). Patients with
OA-MCL frequently presented with disseminated lymphoma (n = 34 of 55; 62%), and were
likely to experience stage IVE disease (n = 35 of 55; 64%), with bilateral involvement (n = 27
of 55; 47%), tumor masses (n = 27 of 36; 75%), and involvement of the orbit (n = 32 of 55;
58%). Chemotherapy with or without external beam radiation therapy was themost
frequently used treatment. Overall survival rates for the entire cohort were 65% at 3 years
(95% CI, 52%-78%) and 34% at 5 years (95% CI, 21%-47%). Disease-specific survival after
5 years was 38% for the entire cohort (95% CI, 25%-51%); the disease-specific survival
adjusted by eye cancer center was better in patients who had received rituximab in addition
to the chemotherapy regimen (hazard ratio, 3.3; 95% CI, 1.0-14.7; P = .06). Themedian
progression-free survival was 2.3 years (95% CI, 1.8-2.7 years) in patients who experienced
recurrence after primary treatment, and 4.1 years (95% CI, 3.9-4.3 years) in patients who
presented with a relapse of systemic lymphoma in the ocular adnexal region.
CONCLUSIONS AND RELEVANCE These results suggest that the distinctive features of OA-MCL
are its appearance in older male individuals, advanced stage and bilateral manifestation at the
time of diagnosis, and aggressive course. The prognosis of patients with OA-MCLmight be
improved by addition of rituximab to chemotherapy treatment.
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M antle-cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma that originates in peripheral Bcells of the innermantle zone. It is characterized by
chromosomal translocation t(11;14)(q13;q32),which results in
upregulation of BCL-1, the gene that encodes protein cyclin
D-1.1-4Mantle-cell lymphoma accounts for approximately 9%
of all cases of non-Hodgkin lymphoma. The annual incidence
of this subtype has increased during recent decades to 1 to 2
per 100000 persons.2
Mantle-cell lymphomaisadiseaseofolder individuals (me-
dianage, 71 years) and ismore common inmen than inwomen
by a ratio of 3:1.1,5-8 The clinical course ofMCL is typically ag-
gressive; it usually presents with widespread disease and is
characterized by frequent recurrences and a poor survival
rate.1,2,8-10 In the past, management had been limited to pal-
liative therapy, which mainly consisted of anthracycline-
based chemotherapy.11,12 During recent decades, however,
novel strategies combining chemotherapy such as cyclophos-
phamide, hydroxydaunorubicin, vincristine, and prednisone
(CHOP)withanti-CD20agent rituximab (R-CHOP)have shown
improved response rates and survival rates.13,14
Mantle-cell lymphoma in theocular adnexa represents2%
to 7% of all non-Hodgkin lymphomas.15-19 Clinicopathologi-
cal reports of ocular adnexal MCL (OA-MCL) have been pub-
lished inonlya fewstudies9,20,21witha limitednumberofcases
(mean, 7), typically involvinga singleeyecancer center.There-
fore, the aim of the present study is to evaluate the clinico-
pathological features of OA-MCL in a large cohort of patients
from 6 eye cancer centers.
Methods
Study Design
Eligible patients with a diagnosis of OA-MCL were identified
fromthedatabasesof6eyecancer centers. Thecaseswere col-
lected via a review of medical records from January 1, 1980,
through December 31, 2015.
For histopathological examination, the specimens were
stainedwith hematoxylin-eosin and analyzed immunohisto-
chemically using the following panel of antibodies known to
be clinically significant in lymphoma: Bcl-2 , Bcl-6, CD3, CD5,
CD10, CD20, CD23, and CD79a; cyclin D-1; and MIB-1, an an-
tibody used to establish the presence of Ki-67, a protein asso-
ciatedwith cellular proliferation. Because the data collection
spanned 36 years and encompassed 6 international eye can-
cer centers, not all the sampleswere analyzed in this uniform
manner. However, all cancer centers had subsequently re-
viewed the specimens independently of the study andhad re-
classified them according to the World Health Organization
publication Classification of Tumours of Haematopoietic and
Lymphoid Tissues22 and, where required, performed addi-
tional immunostaining.
The study followed the tenets of the Declaration of Hel-
sinki and the US Health Insurance Portability and Account-
ability Act of 1996. Institutional review board and health in-
formation privacy agency approvals were obtained from the
Danish Data Protection Agency and local ethics committees,
and the study followed standard consent procedures for oral
and/or written consent in each location.
Clinical Data
The following clinical data were recorded: age and sex of the
patient, symptoms, clinical findings, laterality, systemic in-
volvement according to theAnnArbor staging classification,23
year of diagnosis (before or after the US Food and Drug Ad-
ministration approval of rituximab in 1997), treatment ap-
proaches, response to therapy, survival duration, and cause
of death.
Systemic involvementandlateralityweredeterminedusing
clinical information and diagnostic tools available at the time
of diagnosis. Currently, a complete diagnostic procedure in-
cludes a positron emission tomography/computed tomogra-
phy scan of the entire body, computed tomography or mag-
netic resonance imaging of the ocular adnexal region, and a
bone-marrow biopsy.
Primary ocular adnexal lymphoma is defined as a biopsy-
verified lymphoma in the orbit, conjunctiva, lacrimal gland,
lacrimal sac, and/or eyelids, without history of systemic lym-
phoma. Stage IE disease is limited to the ocular adnexal re-
gion (whereE indicates the involvementof theextranodal site),
while stage IIE indicates involvement of unilateral preauricu-
laror submandibular lymphnodesoradjacentstructures.Stage
IVE indicates involvement of 1 or more organs or tissues out-
side the lymphatic system. Each sample in the present study
was assessed for stage, and the extent of ocular adnexal in-
volvementof primary lymphomaswas evaluatedaccording to
the eighth edition of the American Joint Committee on Can-
cer (AJCC)TNMstagingsystemforocularadnexa lymphoma.24
Statistical Analysis
Overall survival, disease-specific survival (DSS), andprogres-
sion-free survival were considered the primary end points.
Overall survivalwasdefinedas the lengthof time fromthedate
of diagnosis to thedate of death fromany cause (or to thedate
of last contact, a censoredevent).Disease-specific survivalwas
defined as the time from the date of diagnosis to the date of
death from lymphoma (or to the date of last contact, a cen-
sored event). Progression-free survival was calculated as the
time from the date of diagnosis to either the date of first re-
lapse or first sign of progression after initial treatment; in this
Key Points
Question What are the clinical features of ocular adnexal
mantle-cell lymphoma (OA-MCL)?
Findings This retrospective multicenter study included 55
patients, largely elderly andmale, with stage IVE OA-MCL
involving bilateral tumor masses (frequently affecting the orbit).
Five-year disease-specific survival was 38%, which can potentially
be improved through the addition of rituximab to the
chemotherapy treatment.
Meaning Ocular adnexal MCL tends to manifest as bilateral tumor
masses of the orbit, most often in men; it has an aggressive clinical
course with poor prognosis.
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case, thedateofdeath fromanycause and thedateof last con-
tactwerebothconsideredcensoredevents.Kaplan-Meierplots
were generated to visualize survival outcomes, and different
risk groups were compared using the log-rank test. Indi-
vidual risk factors were compared using the χ2 test. Cox pro-
portional hazardmodeling was used to estimate each hazard
ratio (HR). Statistical calculationswere performedusing SPSS
Statistics version 22 (IBM Corporation).
Results
A total of 55 patients with OA-MCL were identified from the
databases of eye cancer centers in Copenhagen, Denmark
(n = 27);Houston, Texas (n = 14); Liverpool, England (n = 10);
NewYork,NewYork (n = 2); Atlanta, Georgia (n = 1); andMel-
bourne, Victoria, Australia (n = 1). Selected patient data from
the cancer centers in Copenhagen, New York, and Houston
were previously published in local studies on various histo-
logic subtypes of ocular adnexal lymphoma.9,19,25
Forty-two of the patients were male (76%) (Table 1). The
mean age was 70 years (range, 34-90 years), and the median
follow-uptimewas33months(range,1-162months).Thepatients
werepredominantlywhite (n = 37of41; 90%).Tumoror swell-
ing (n = 22of29;76%)and irritation (n = 15of29;52%)were the
most commonsymptoms (Figure 1). Themediansymptomdu-
ration was 6months (range, 1-24months). Themost common
clinical signswereamass (n = 27of36;75%)andglobedisplace-
ment(n = 9of36;25%).Serumlactatedehydrogenaselevelswere
available in 19 patients, ofwhom 12 (63%) had elevated levels.
Table 1. Clinical and Staging Characteristics of 55 PatientsWith Ocular Adnexal Mantle-Cell Lymphoma
Characteristic










Male 42 (76) 7 25 10
Female 13 (24) 1 9 3
Age, y
≤60 5 (9) 0 3 2
>60 50 (91) 8 31 11
Laterality
Unilateral 29 (53) 6 15 8
Bilateral 26 (47) 2 19 5
Ann Arbor stage
IE 9 (16) 7 0 2
IIE 5 (9) 1 4 0
IIIE 6 (11) 0 4 2
IVE 35 (64) 0 26 9
Initial treatment
EBRT 6 (12) 2 3 1
Rituximab
With CHOP 3 (6) 0 3 0
With CHOP and EBRT 1 (2) 1 0 0
With other chemotherapy 13 (25) 0 9 4
With other chemotherapy
and EBRT
2 (4) 0 1 1
With EBRT 1 (2) 0 1 0
Chemotherapy
CHOP 2 (4) 0 2 0
CHOP and EBRT 2 (4) 0 0 2
Other chemotherapy 11 (22) 0 8 3
Other chemotherapy and EBRT 10 (20) 4 4 2
Recurrence or progression
No 11 (22) 1 5 5
Yes 40 (78) 7 25 8
Disease status at last follow-up
Complete remission 13 (24) 1 10 2
Alive with disease 11 (20) 3 6 1
Dead from lymphoma 27 (49) 4 17 6




EBRT, external beam radiation
therapy.
a Data are not specified for all
patients.
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Eightpatients (15%)werediagnosedwithprimaryOA-MCL,
34 (62%) had systemic lymphoma with an additional mani-
festation in the ocular adnexa, and 13 (24%) presentedwith a
relapse of systemic lymphoma in the ocular adnexal region.
Of the 8 patients with primary lymphomas, 6 had unilateral
disease (75%).Bilateralmanifestationwascommonamongpa-
tients with disseminated OA-MCL (n = 19 of 34; 56%) and re-
lapsed disease (n = 5 of 13; 38%).
The orbit was the most frequently involved ocular ad-
nexal site among patients with primary OA-MCL (n = 6 of 8;
75%), as well as disseminated (n = 19 of 34; 56%), and re-
lapseddisease (n = 7of 13; 54%) (Table2). Theconjunctivawas
likewise frequently involved in 25% (n = 2 of 8), 35% (n = 12
of 34), and 23% (n = 3 of 13) of primary, disseminated, and re-
lapsed OA-MCL, respectively.
Clinical Staging of OA-MCL
According to the Ann Arbor staging system,23 7 of the 8 pa-
tients with primary OA-MCL were initially seen with stage IE
disease, while patients with disseminated and relapsed
OA-MCL predominantly had stage IVE disease at diagnosis
(n = 26 of 34, 76%; n = 9 of 13, 69%) (Table 1).
TheAJCCTNMstagingwasperformedinthe8patientswith
primary lymphomatousdisease.Of thesepatients, 6had stage
T2 disease (involving the orbit with or without the lacrimal
gland) and 2 had stage T3 disease (which involved the prese-
ptal eyelids). The posterior orbit (T2c) was the most fre-
quently involvedsite inT2disease, followedby theanterioror-
bitwithout the lacrimal gland (T2a). Lymphnode involvement
(TxN1Mx, per AJCC stages) was present in 1 of the 8 patients.
Treatment
Chemotherapy with or without external beam radiation
therapy (EBRT) was the most frequently used treatment ap-
proach among primary, disseminated, and relapsed lympho-
mas (50%, 41%, and 53%, respectively) (Table 1). Themedian
prescribed EBRT dose was 30 Gy (range, 4-50 Gy). (To con-
vert to rad,multiply by 100.) Theapplied chemotherapy types
includedCHOP,alkylatingagents, andchemotherapyunspeci-
fied in medical records. Rituximab in combination with che-
motherapy (with orwithout EBRT)was used in the treatment
of 19 of 51 patients in the study (37%), all of whom had stage
IVEdisease,with theexceptionof 1personwithdiseaseat stage
IE.Amongstage IVE lymphomas, this treatment approachwas
applied more frequently in Houston (n = 10 of 13; 77%) com-
paredwith the remainingeyecancer centers (n = 8of20;40%)
(Table 3).
Treatment Outcomes and Survival
Median follow-up timewas 33months (range, 1-162months).
Recurrenceorprogressionwasobserved in84%ofpatients (32
of 38; 95% CI, 72-96) after primary treatment, and in 62% of
patients (8 of 13; 95%CI, 36-88)who presentedwith a relapse
of systemic lymphoma in the ocular adnexal region (Table 1).
The median progression-free survival was 2.3 years (95% CI,
1.8-2.7 years) and 4.1 years (95% CI, 3.9-4.3 years), respec-
tively. The site of relapse was accessible in 29 patients with
OA-MCL, of whom 8 had recurrence within the ocular ad-
nexal region (5 of these had involvement in the orbit), 14 had
ocular adnexal recurrence in conjunction with nodal and/or
extranodal involvement, and7had recurrence innodal and/or
extranodal sites outside the ocular adnexal region.
Survivaldatawereavailable forall 55patients.TheOSrates
for the entire cohort were 65% at 3 years (95% CI, 52%-78%)
and 34% at 5 years (95% CI, 21%-47%). The 3-year and 5-year
DSS rateswere72%(95%CI,60%-84%)and38%(95%CI, 25%-
51%), respectively.
The 5-year DSS was not significantly different in patients
with primary, disseminated, or relapsed lymphoma and was
likewisenotassociatedwithAnnArbor stageofdisease (P = .27
andP = .42, respectively).The5-yearDSSwasbetter amongpa-
tientswithdisseminated lymphomadiagnosedafter 1997 (57%;
95%CI,42%-72%) thanthosediagnosedbefore 1997 (22%;95%
CI,9%-35%) (P = .04). Since rituximabtreatmentbecameavail-
able in 1997, patients with stage IVE disease receiving ritux-
imab in addition to chemotherapy (withorwithoutEBRT)had
abetter 5-yearDSS (79%;95%CI, 65%-93%) thanpatientswho
were not treated with rituximab (25%; 95% CI, 11%-39%)
Figure 1. Disease-Specific Survival Among PatientsWith Stage IVEOcular Adnexal Mantle-Cell Lymphoma














































had a better outcome than patients
receiving chemotherapy without
rituximab since rituximab became
available in 1997. Hashmarks indicate
the occurrence of a censoring event.
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(P = .04) (Figure 2). The 5-year DSSwas better among patients
withdisseminated lymphomafromHouston (100%) than from
Liverpool (0%;P = .01)andwasmorefavorable forpatientswith
stage IVEdisease fromHouston(100%)thanpatientswithstage
IVE disease fromCopenhagen (28%; P = .005) (Table 3). After
adjusting for eye cancer center, patients receiving rituximab in
Table 2. Location, Frequency of Symptoms, and Clinical Signs at Presentation of Ocular Adnexal
Mantle-Cell Lymphoma
Characteristic









Location in the ocular
adnexal region
Orbit 32 (58) 6 19 7
Conjunctiva 17 (31) 2 12 3
Lacrimal gland 8 (15) 0 7 1
Eyelid 9 (16) 2 6 1
Lacrimal sac 1 (2) 0 0 1
Symptom
Tumor or swelling 22 (76) 2 10 10
Irritation or pain 15 (52) 2 8 5
Epiphora 13 (45) 2 6 5
Exophthalmus 5 (17) 1 3 1
Diplopia 6 (21) 0 6 0
Ptosis 3 (10) 0 2 1
Decreased visual activity 1 (3) 0 1 0
B symptomsb 6 (21) 0 5 1
Not stated 26 (47) 6 17 3
Clinical sign
Mass 27 (75) 2 16 9
Globe displacement 9 (25) 2 6 1
Chemosis 7 (19) 2 4 1
Restricted eye movement 4 (11) 1 3 0
Resistance 2 (6) 1 1 0
Edema 2 (6) 0 1 1
Diplopia 6 (17) 1 5 0
Ptosis 2 (6) 0 1 1
Epiphora 3 (8) 1 2 0
Not stated 19 (35) 6 10 3
a A total of more than 100% because
patients may have presenting
symptoms or signs in more than one
location.
bB symptoms are defined as night
sweats, fever, and weight loss.
Table 3. Treatment andOutcome of PatientsWithMantle-Cell Lymphoma in All Eye Cancer Centers
Status
Eye Cancer Center, Patients, No. (%)a
Copenhagen, Denmark Houston, Texas Liverpool, England Otherb
<IVE IVE <IVE IVE <IVE IVE <IVE IVE
Total 9 18 1 13 8 2 2 2
Treatment
EBRT 2 (25) 0 1 (100) 0 0 2 (100) 0 1 (50)
CTX ± EBRT 5 (63) 9 (53) 0 2 (15) 8 (100) 0 1 (50) 0
Rituximab and CTX ± EBRT 1 (11) 8 (47) 0 10 (77) 0 0 0 0
Rituximab and EBRT 0 0 0 1 (8) 0 0 0 0
Status at last follow-up
Complete remission 3 (33) 5 (28) 0 2 (15) 0 0 1 (50) 2 (100)
Alive with disease 2 (22) 1 (6) 0 6 (46) 1 (13) 0 1 (50) 0
Died of lymphoma 4 (44) 11 (61) 1 (100) 2 (15) 7 (88) 2 (100) 0 0
Died of other causes 0 1 (6) 0 3 (21) 0 0 0 0
Abbreviations: CTX, chemotherapy; EBRT, external beam radiation therapy.
a Data are not specified for all patients.
bOther locations are Atlanta, Georgia; New York, New York; andMelbourne,
Victoria, Australia.
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addition to chemotherapy (with or without EBRT) had a bet-
ter disease-specific survival at 5 years than patients who did
not receive rituximab (HR, 3.3; 95% CI, 1.0-14.7; P = .06).
Discussion
OcularadnexalMCLwasfoundtopresentprimarily inoldermale
individuals, and it appeared tobeanaggressivemalignant con-
ditionwith a frequent occurrence of dissemination (62%; 95%
CI,49%-75%),bilateralocularadnexalmanifestation(47%;95%
CI, 34%-60%), and a poor prognosis (5-year DSS, 38%; 95%CI,
24%-50%),whichcouldpotentiallybe improvedbyadditionof
rituximab to the chemotherapy regimen.
ThepredominanceofOA-MCLamongoldermale individu-
als,asdetected inthisstudy, isconsistentwiththeresultsofpre-
vious research.1,5-8 The sexdifference associatedwith this dis-
ease isamongthemostpronouncedin lymphoma,withasimilar
male predominance found only in hairy-cell leukemia (which
has amale–female ratio of 3.3:1) andBurkitt lymphoma (with a
male–female ratio of 3.1:1).26 Genetic studies propose that this
striking sexdifferencemightbeexplainedbyanage-relatedef-
fect inolder cells that increases the riskof lossof sectionsof the
Y chromosome, in combination with the suppression of a tu-
mor suppressor gene on the X chromosome.27
The high proportion of disseminated lymphoma identi-
fied in the present study is likewise in accordancewith previ-
ous studies of MCL.1,2,8,9 The tendency for lymphoma to dis-
seminate throughout the body is probably related to the
derivation of MCL from pregerminal center B lymphocytes,
whichexpress specific adhesionmolecules andchemokine re-
ceptors that allow them to circulate continuously to second-
ary lymphoid tissues.28 This predisposition toward wide-
spread disease likely explains the high proportion of bilateral
disease identified among OA-MCLs in this study.
Current lymphoma treatment guidelines recommend
R-CHOP or similar chemotherapy for management of MCL at
all stages.2 This approachwas only used to treat 19 patients in
thepresent study,whichmight be because the study spanned
a 36-year period, and rituximab has only been available since
1997.29
The presented data confirm that MCL has a poor
prognosis.1,15,16,30-32Asother studieshave shown, survival can
potentially be improved by the addition of rituximab to che-
motherapy treatment.13,14 The fact that patients from Hous-
tonhadabetter outcome thanpatients fromLiverpool andCo-
penhagen may be explained in part by the higher proportion
of patients fromHoustonwhowere diagnosed after 1997 and
whoconsequently receivedrituximab incombinationwithche-
motherapy. Studying patients with primary OA-MCL across
relatively similar lengths of the follow-up period established
that all had recurrences after treatment except 1 patient, who
had received rituximab-containing chemotherapy. There-
fore, the present findings highlight the importance of adding
rituximab to the chemotherapy treatment, including in pa-
tients whose OA-MCL is localized.
Limitations
The retrospectivedesignof thismulticenter studyposes some
inherent limitations. The datawere pooled across 6 oncology
centersovera36-yearperiod,whichentailed incompletemedi-
cal records and varying diagnostic and treatment methods,
whichmade evaluation of treatment approaches particularly
challenging. As the present study dealswith a rare subtype of
lymphoma in theocular adnexa, thenumberofpatients is low.
This makes it less certain that these findings are truly repre-
sentative. Furthermore, themedian follow-upwas33months,
which might not have been enough time to detect the out-
come variables in some cases. On the other hand, multi-
center studies like this, obtaining a reasonable number of pa-
tients, provide valuable information on relatively rare lesions
such as OA-MCL.
Conclusions
The results of this study confirm thatOA-MCLmanifestsmost
commonly in older men. The clinical course of this disease
Figure 2. Clinical, Magnetic Resonance Imaging, and Histological
Findings ofMantle-Cell Lymphoma
Clinical presentation right eyeA Clinical presentation left eyeB
Magnetic resonance imageC Hematoxylin-eosin stainD
Anti-K antibody immunostainE Anti-cyclin D-1 immunostainF
A and B, Clinical presentation of mantle-cell lymphomawith bilateral
involvement of the conjunctiva. C, Image shows conjunctival and orbital tumor
masses (arrowheads). D, Mantle-cell lymphoma showing amonotonous pattern
of small cells with irregular nuclei with inconspicuous nucleoli and scant
cytoplasm. E, The tumor cells bind anti-κ antibodies. F, The tumor cells react
with anti-cyclin D-1.
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appears to be aggressive, with patients frequently presenting
with disseminated lymphoma at stage IVE, with bilateral tu-
mormasses that frequently involve theorbit. Treatment com-
monly requires chemotherapy, with or without EBRT. These
data suggest that theprognosis for thesepatients is poor; how-
ever, the findings suggest that survival can potentially be im-
proved by addition of rituximab to the chemotherapy regi-
men. Further research is necessary to identify more clinical
features associated with earlier detection of MCL in patients
with OA-MCL to potentially improve their prognosis.
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